Search 

Achilles Therapeutics is a biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens: protein markers unique to each individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. Targeting multiple clonal neoantigens that are present on all cancer cells, but not on healthy cells, allows individualised treatments to target and destroy tumours without harming healthy tissues.

Albumedix is an integrated biotech company with a strong pipeline of  albumin-enabled therapeutics developed by partners (incl. CSL Behring, Merck & GSK) utilizing our innovative albumin-based, drug enhancing products and technologies.

Arctoris Ltd is an Oxford-based startup revolutionising cancer research by combining robotics & AI. Arctoris enables researchers to configure their experiments remotely and have them executed in a fully automated cloud laboratory.

CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer, heart disease, osteoarthritis and diabetic wound healing. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health.

Enesi Pharma is an early stage pharmaceutical company developing innovative needle-free solid dose vaccine products with potential to transform performance and delivery of vaccines and make a material impact on global healthcare.

Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system.

Mereo BioPharma is an innovative leader in the biopharma sector with a focus on developing and optimizing the value of novel medicines acquired from large pharmaceutical companies designed to address significant unmet medical needs in rare and specialty disease areas. Mereo has built an initial mid-late stage portfolio of four exceptionally well characterised novel products, three from Novartis and one from AstraZeneca, for the treatment of diseases with considerable unmet medical need.

Therakind is a specialty pharmaceutical company focused on developing medicines in difficult-to-treat markets including paediatric and geriatric patient groups. Out-licensing Jylamvo® oral liquid methotrexate & DriDose® novel nasal powder delivery device.

XenoGesis Ltd. is a laboratory-based contract research organisation (CRO) specialised in preclinical drug metabolism & pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. The core XenoGesis team has an enviable track record of delivery in drug discovery.

It is clear that identifying poor compounds early through scientific rigor is key in preventing progression into more expensive pre-clinical tests. Even a minor improvement in early-stage drug failure prediction will result in significant time and cost savings for R&D companies. Specifically,XenoGesis can identify the potential 'winners' and 'losers' in a selection of compounds synthesised in drug discovery campaigns. Moreover, providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis.

To read the latest XenoGesis news CLICK HERE.